All three of these high-flying stocks could have more room to run.
A recent FDA announcement may have just put one company in the lead.
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.
Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's...
Even more revenue is on the way from additional sales of Wegovy.
Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.
Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?
What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.23%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.37%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...